BIGBEAR
PHARMACEUTICALS
Enasidenib's innovative therapy offers a new treatment option for AML patients who are unresponsive to or experience relapse with conventional therapies.
AuthenticGuaranteeFast DeliveryPrivacy August 1, 2017 – The U.S. Food and Drug Administration (FDA) approved enasidenib for the treatment of adult patients with relapsed or refractory acute···【Read More】
Update: 10 Mar,2026Source: Haiou HealthViews: 73
In addition to the expected therapeutic effects, some adverse reactions may occur when receiving enasidenib treatment. While not all side effects will···【Read More】
Update: 10 Mar,2026Source: Haiou HealthViews: 72
On November 29, 2018, the U.S. Food and Drug Administration (FDA) warned that symptoms of differentiation syndrome, a life-threatening side effect of ···【Read More】
Update: 10 Mar,2026Source: Haiou HealthViews: 73
On November 29, 2018, the U.S. Food and Drug Administration (FDA) warned that symptoms of differentiation syndrome, a life-threatening side effect of ···【Read More】
Update: 09 Mar,2026Source: Haiou HealthViews: 72
Enasidenib was developed by Celgene in the United States and approved for marketing by the US FDA on August 1, 2017.Enasidenib (EnglishIndications)Ena···【Read More】
Update: 09 Mar,2026Source: Haiou HealthViews: 73
Enasidenib is indicated for adult patients with relapsed or refractory acute myeloid leukemia (AML) who have been diagnosed with an isocitrate dehydro···【Read More】
Update: 09 Mar,2026Source: Haiou HealthViews: 73
Copyright2024@ BIGBEAR All right reserved BIGBEAR
